Evidence map›Paper›PMID 42120551›Full record

ArticleScientific reports2026

Tellurium-118 as a novel radionuclide for long-term positron emission tomography.

Sotaro Miyao, Toshimitsu Momose, Masako Kawabata, Yuki Mitsuya, Atsuko Nakanishi Ozeki, Arisa Hayashi, Xindi Qiu, Yousuke Kanayama, Hiromitsu Haba, Izumi O Umeda and 4 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sotaro MiyaoIsotope Science Center, The University of Tokyo, Tokyo, 113-0032, Japan.
Toshimitsu MomoseDepartment of Biofunctional Imaging, Fukushima Medical University, Fukushima, 960-1295, Japan.
Masako KawabataOarai Research Center, Chiyoda Technol Corporation, Ibaraki, 311-1313, Japan.
Yuki MitsuyaInstitute of Engineering Innovation, The University of Tokyo, Tokyo, 113-8656, Japan.
Atsuko Nakanishi OzekiIsotope Science Center, The University of Tokyo, Tokyo, 113-0032, Japan.
Arisa HayashiIsotope Science Center, The University of Tokyo, Tokyo, 113-0032, Japan.
Xindi QiuIsotope Science Center, The University of Tokyo, Tokyo, 113-0032, Japan.
Yousuke KanayamaNishina Center for Accelerator-Based Science, RIKEN, Wako, Saitama, 351-0198, Japan.
Hiromitsu HabaNishina Center for Accelerator-Based Science, RIKEN, Wako, Saitama, 351-0198, Japan.
Izumi O UmedaFaculty of Medical Science, Kyoto University of Medical Science, Kyoto, 622-0041, Japan.
Jaewoong JangIsotope Science Center, The University of Tokyo, Tokyo, 113-0032, Japan.
Youichiro WadaIsotope Science Center, The University of Tokyo, Tokyo, 113-0032, Japan.
Nobuyoshi AkimitsuIsotope Science Center, The University of Tokyo, Tokyo, 113-0032, Japan.
Hiroyuki TakahashiInstitute of Engineering Innovation, The University of Tokyo, Tokyo, 113-8656, Japan. leo@n.t.u-tokyo.ac.jp.

Funding

F-REI JPFR2504030JSPS KAKENHI 22H04961JSPS KAKENHI 22KK0108JSPS KAKENHI 25K18923
6 · The paper itself

Abstract

Positron emission tomography (PET) is a powerful imaging modality that tracks positron-emitting radionuclides, enabling non-invasive and high-resolution visualization of biological targets and processes. However, conventional PET tracers possess short half-lives, which limits their utility for long-term pharmacokinetic studies of slow-clearing agents such as antibodies. To address this unmet need, we developed and evaluated tellurium-118 (118Te), a long-lived radionuclide (T₁/₂ = 6.0 days) that decays via electron capture to produce antimony-118 (118Sb), a short-lived positron emitter (T₁/₂ = 3.5 min). This decay cascade allows 118Te to function as an in vivo radionuclide generator, providing sustained positron emission from a single administration. We successfully produced 118Te and performed PET imaging with NEMA and Derenzo phantoms, confirming its PET images with sufficient spatial resolution. In vivo PET/CT imaging of mice following intravenous administration of 118Te revealed the persistence of PET signals in the abdominal region up to three weeks post-injection. Ex vivo biodistribution analysis confirmed the prolonged retention of radioactivity in abdominal organs, particularly the liver and spleen. These findings demonstrate the feasibility of 118Te as a long-lived PET radionuclide for extended molecular imaging. Its unique decay profile and sustained signal generation make it a promising candidate for longitudinal pharmacokinetic studies and radiotheranostic applications.

Indexed as

AVF cyclotronComputed tomographyLong-lived radionuclidePositron emission tomographyRadiotheranosticsTargeted radioligand therapy

Identifiers

PMID42120551
PMCPMC13168239

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.